P1028: PTG-300 (RUSFERTIDE) TREATMENT INTERRUPTION REVERSES HEMATOLOGICAL GAINS AND RESTORES THERAPEUTIC BENEFIT ON REINITIATION IN SUBJECTS WITH POLYCYTHEMIA VERA

• A. Kuykendall,
• M. Kremyanskaya,
• Y. Ginsburg,
• N. Pemmaraju,
• E. Ritchie,
• J. Gotlib,
• F. Valone,
• S. Khanna,
• S. Gupta,
• R. Hoffman,
• S. Verstovsek

Affiliations

A. Kuykendall

1 Hematology and Med Oncology, USF, Moffitt Cancer Center, Tampa

M. Kremyanskaya

2 Hematology, Mt. sinai, New york

Y. Ginsburg

2 Hematology, Mt. sinai, New york

N. Pemmaraju

3 Dept of Leukemia, M.D. Anderson, Houston, Tx

E. Ritchie

4 Hematology, Weill Cornell medical College, New york

J. Gotlib

5 Hematology, school of Medicine, Stanford, Palo Alto, Ca

F. Valone

6 Clinical Research and Development, Protagonist Therapeutics, Newark, United States of America

S. Khanna

6 Clinical Research and Development, Protagonist Therapeutics, Newark, United States of America

S. Gupta

6 Clinical Research and Development, Protagonist Therapeutics, Newark, United States of America

R. Hoffman

2 Hematology, Mt. sinai, New york

S. Verstovsek

3 Dept of Leukemia, M.D. Anderson, Houston, Tx